Beta Bionics (Nasdaq:BBNX) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast.
Shares of BBNX rose around 20% to $29 apiece in post-market trading today.
The Irvine, California-based automated insulin delivery device maker reported losses of $14 million. That equals 33¢ per share on sales of $27.25 million for the three months ended Sept. 30, 2025.
Beta Bionics — one of the largest diabetes tech companies in the world — recorded a 45% bottom-line slide on a sales increase of 63.1% year-over-year.
Earnings per share landed 8¢ ahead of expectations on Wall Street. Sales also topped the forecast as experts projected $24 million in revenue.
The rollout of the iLet bionic pancreas system continues to support growth, contributing more than $14 million in revenue in the quarter. Beta Bionics said its installed customer base of 29,419 users is up 162% compared to 11,214 in the same period a year ago. The company reported 5,334 new patient starts, up 68% compared to 3,180 new patient starts in the third quarter of 2024. Nearly three quarters (70%) of those came from people on multiple daily injections.
Beta Bionics raised its full-year guidance on the back of the results. It now expects revenues to surpass $96.5 million, having previously projected between $88 million and $93 million.
The company also raised its estimates for new patient starts reimbursed through the pharmacy benefit plan (PBP) channel. It now expects between 27% and 29%, up from 25% to 28%.
Recent highlights and developments at Beta Bionics
Recent highlights include the unveiling of the “Mint” patch pump in development, plus data on the use of the flagship iLet system in a “fully closed-loop” manner. The company also has effective formulary agreements in place with all major pharmacy benefit managers (PBMs) in the U.S. as of July.
Last mont, the company received a special 510(k) clearance related to certain user experience features for iLet. Those include a more seamless cartridge change process and the elimination of redundant low glucose alerts.
Additionally, Beta Bionics said that last month it completed its glucagon pharmacokinetic (PK)-pharmacodynamic (PD) trial in Canada. This would enable it to bridge previous bihormonal clinical data now that it has a glucagon asset developed by Xeris. Results are in line with management expectations and the company believes findings support the continued development of the glucagon asset for use with the system.
The company plans to initiate a feasibility trial in New Zealand for the bihormonal system in the fourth quarter of 2025. It would include the pump and dosing algorithms, marking their first use in humans with the new glucagon asset.
Founder Ed Damiano spoke earlier this year about plans for the bihormonal system, among other expectations at the company.
